IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-β receptor on hepatic stellate cells in a JNK-dependent manner

Journal of Immunology

Volumn 193, Issue 8, 2014, Pages 3925-3933

  Fabre, Thomas ^a,b   Kared, Hassen ^a   Friedman, Scott L ^c   Shoukry, Naglaa H ^a,d  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; INTERLEUKIN 17; SMAD2 PROTEIN; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; ACTA2 PROTEIN, HUMAN; ACTIN; COLLAGEN TYPE I, ALPHA 1 CHAIN; IL17A PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER FIBROSIS; NUCLEOTIDE SEQUENCE; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STELLATE CELL; BIOSYNTHESIS; CELL LINE; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; UPREGULATION;

ACTINS; CELL LINE; COLLAGEN TYPE I; GENE EXPRESSION REGULATION; HEPATIC STELLATE CELLS; HUMANS; INTERLEUKIN-17; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER; LIVER CIRRHOSIS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84907485547     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400861     Document Type: Article

References (42)

1. Hernandez-Gea, V., and S. L. Friedman. 2011. Pathogenesis of liver fibrosis. Annu. Rev. Pathol. 6: 425-456.
2. Friedman, S. L. 2008. Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669.
3. Weng, H. L., Y. Liu, J. L. Chen, T. Huang, L. J. Xu, P. Godoy, J. H. Hu, C. Zhou, F. Stickel, A. Marx, et al. 2009. The etiology of liver damage imparts cytokines transforming growth factor b1 or interleukin-13 as driving forces in fibrogenesis. Hepatology 50: 230-243.
4. Siefert, S. A., and R. Sarkar. 2012. Matrix metalloproteinases in vascular physiology and disease. Vascular 20: 210-216.
5. Murphy, G. 2011. Tissue inhibitors of metalloproteinases. Genome Biol. 12: 233.
6. Greene, R. M., P. Nugent, P. Mukhopadhyay, D. R. Warner, and M. M. Pisano. 2003. Intracellular dynamics of Smad-mediated TGFβ signaling. J. Cell. Physiol. 197: 261-271.
7. Inagaki, Y., and I. Okazaki. 2007. Emerging insights into transforming growth factor b Smad signal in hepatic fibrogenesis. Gut 56: 284-292.
8. Barron, L., and T. A. Wynn. 2011. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am. J. Physiol. Gastrointest. Liver Physiol. 300: G723-G728.
9. Baroni, G. S., L. D'Ambrosio, P. Curto, A. Casini, R. Mancini, A. M. Jezequel, and A. Benedetti. 1996. Interferon g decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 23: 1189-1199.
10. Chiaramonte, M. G., D. D. Donaldson, A. W. Cheever, and T. A. Wynn. 1999. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J. Clin. Invest. 104: 777-785.
11. Mentink-Kane, M. M., A. W. Cheever, M. S. Wilson, S. K. Madala, L. M. Beers, T. R. Ramalingam, and T. A. Wynn. 2011. Accelerated and progressive and lethal liver fibrosis in mice that lack interleukin (IL)-10, IL-12p40, and IL-13Rα2. Gastroenterology 141: 2200-2209.
12. Zhang, L., X. Wang, W. Zheng, and M. Shi. 2006. The effects of interleukin-10 on the expression of Fas and FasL in rat hepatic stellate cells. Med. Chem. 2: 611-616.
13. Zhang, L. J., W. D. Zheng, M. N. Shi, and X. Z. Wang. 2006. Effects of interleukin-10 on activation and apoptosis of hepatic stellate cells in fibrotic rat liver. World J. Gastroenterol. 12: 1918-1923.
14. Bettelli, E., T. Korn, M. Oukka, and V. K. Kuchroo. 2008. Induction and effector functions of TH17 cells. Nature 453: 1051-1057.
15. Korn, T., M. Oukka, V. Kuchroo, and E. Bettelli. 2007. Th17 cells: effector T cells with inflammatory properties. Semin. Immunol. 19: 362-371.
16. Bengsch, B., B. Seigel, T. Flecken, J. Wolanski, H. E. Blum, and R. Thimme. 2012. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J. Immunol. 188: 5438-5447.
17. Foster, R. G., L. Golden-Mason, A. Rutebemberwa, and H. R. Rosen. 2012. Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig. Dis. Sci. 57: 381-389.
18. Lemmers, A., C. Moreno, T. Gustot, R. Maréchal, D. Degré, P. Demetter, P. de Nadai, A. Geerts, E. Quertinmont, V. Vercruysse, et al. 2009. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 49: 646-657.
19. Zhang, J. Y., Z. Zhang, F. Lin, Z. S. Zou, R. N. Xu, L. Jin, J. L. Fu, F. Shi, M. Shi, H. F. Wang, and F. S. Wang. 2010. Interleukin-17-producing CD4+ T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 51: 81-91.
20. Gaffen, S. L. 2009. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9: 556-567.
21. Kluwe, J., J. P. Pradere, G. Y. Gwak, A. Mencin, S. De Minicis, C. H. Osterreicher, J. Colmenero, R. Bataller, and R. F. Schwabe. 2010. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 138: 347-359.
22. Meng, F., K. Wang, T. Aoyama, S. I. Grivennikov, Y. Paik, D. Scholten, M. Cong, K. Iwaisako, X. Liu, M. Zhang, et al. 2012. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143: 765-776.e3.
23. Sparna, T., J. Rétey, K. Schmich, U. Albrecht, K. Naumann, N. Gretz, H. P. Fischer, J. G. Bode, and I. Merfort. 2010. Genome-wide comparison between IL-17 and combined TNF-α/IL-17 induced genes in primary murine hepatocytes. BMC Genomics 11: 226.
24. Tan, Z., X. Qian, R. Jiang, Q. Liu, Y. Wang, C. Chen, X. Wang, B. Ryffel, and B. Sun. 2013. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J. Immunol. 191: 1835-1844.
25. Yan, S., L. Wang, N. Liu, Y.Wang, and Y. Chu. 2012. Critical role of interleukin-17/interleukin-17 receptor axis in mediating Con A-induced hepatitis. Immunol. Cell Biol. 90: 421-428.
26. Wilson, M. S., S. K. Madala, T. R. Ramalingam, B. R. Gochuico, I. O. Rosas, A. W. Cheever, and T. A. Wynn. 2010. Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207: 535-552.
27. Xu, L., A. Y. Hui, E. Albanis, M. J. Arthur, S. M. O'Byrne, W. S. Blaner, P. Mukherjee, S. L. Friedman, and F. J. Eng. 2005. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54: 142-151.
28. Melisi, D., S. Ishiyama, G. M. Sclabas, J. B. Fleming, Q. Xia, G. Tortora, J. L. Abbruzzese, and P. J. Chiao. 2008. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther. 7: 829-840.
29. Seki, E., S. De Minicis, C. H. Osterreicher, J. Kluwe, Y. Osawa, D. A. Brenner, and R. F. Schwabe. 2007. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat. Med. 13: 1324-1332.
30. Liu, Q., Y. Zhang, H. Mao, W. Chen, N. Luo, Q. Zhou, W. Chen, and X. Yu. 2012. A crosstalk between the Smad and JNK signaling in the TGF-β-induced epithelial-mesenchymal transition in rat peritoneal mesothelial cells. PLoS ONE 7: e32009.
31. Wang, X. M., Y. Zhang, H. P. Kim, Z. Zhou, C. A. Feghali-Bostwick, F. Liu, E. Ifedigbo, X. Xu, T. D. Oury, N. Kaminski, and A. M. Choi. 2006. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J. Exp. Med. 203: 2895-2906.
32. Bennett, B. L., D. T. Sasaki, B. W. Murray, E. C. O'Leary, S. T. Sakata, W. Xu, J. C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, et al. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 98: 13681-13686.
33. Heo, Y. S., S. K. Kim, C. I. Seo, Y. K. Kim, B. J. Sung, H. S. Lee, J. I. Lee, S. Y. Park, J. H. Kim, K. Y. Hwang, et al. 2004. Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J. 23: 2185-2195.
34. Marra, F., W. Delogu, I. Petrai, S. Pastacaldi, A. Bonacchi, E. Efsen, S. Aleffi, C. Bertolani, M. Pinzani, and P. Gentilini. 2004. Differential requirement of members of the MAPK family for CCL2 expression by hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 287: G18-G26.
35. Zhao, L., Y. Tang, Z. You, Q. Wang, S. Liang, X. Han, D. Qiu, J. Wei, Y. Liu, L. Shen, et al. 2011. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS ONE 6: e18909.
36. Guillot, A., N. Hamdaoui, A. Bizy, K. Zoltani, R. Souktani, E. S. Zafrani, A. Mallat, S. Lotersztajn, and F. Lafdil. 2013. Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver. Hepatology 59: 296-306.
37. Brembilla, N. C., E. Montanari, M. E. Truchetet, E. Raschi, P. Meroni, and C. Chizzolini. 2013. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res. Ther. 15: R151.
38. Hammerich, L., F. Heymann, and F. Tacke. 2011. Role of IL-17 and Th17 cells in liver diseases. Clin. Dev. Immunol. 2011: 345803.
39. Nair, D. G., K. G. Miller, S. R. Lourenssen, and M. G. Blennerhassett. 2014. Inflammatory cytokines promote growth of intestinal smooth muscle cells by induced expression of PDGF-Rβ. J. Cell. Mol. Med. 18: 444-454.
40. Rozenfeld, R., A. Gupta, K. Gagnidze, M. P. Lim, I. Gomes, D. Lee-Ramos, N. Nieto, and L. A. Devi. 2011. AT1R-CB1R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J. 30: 2350-2363.
41. Das, M., G. Sabio, F. Jiang, M. Rincón, R. A. Flavell, and R. J. Davis. 2009. Induction of hepatitis by JNK-mediated expression of TNF-α. Cell 136: 249-260.
42. Zhao, G., M. Hatting, Y. A. Nevzorova, J. Peng, W. Hu, M. V. Boekschoten, T. Roskams, M. Muller, N. Gassler, C. Liedtke, et al. 2014. Jnk1 in murine hepatic stellate cells is a crucial mediator of liver fibrogenesis. Gut 63: 1159-1172.